share_log

復星醫藥：截至2024年6月30日止六個月之中期業績公告以及更換聯席公司秘書及授權代表

FOSUN PHARMA: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024 AND CHANGE OF JOINT COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

HKEX ·  Aug 27 22:32

Summary by Moomoo AI

上海復星醫藥（集團）股份有限公司公佈截至2024年6月30日止六個月的未經審核中期業績。期內，集團實現收入20,383百萬元，較去年同期下降4.38%；銷售成本為10,463百萬元，下降2.21%。銷售及分銷開支為4,266百萬元，下降15.87%；行政開支為2,149百萬元，上升2.19%。研發費用為1,862百萬元，下降12.75%。其他收益為273百萬元，下降68.14%；其他開支為435百萬元，上升69.92%。應佔聯營企業損益為947百萬元，下降15.30%。經營活動產生的現金流量淨額為1,907百萬元，上升5.36%。此外，公司宣佈更換聯席公司秘書及授權代表，甘美霞女士因到齡退休而辭任，陳秀玲女士接任。公司亦進行了A股回購，累計回購1,457,800股，總金額約為人民幣32.3238百萬元。董事會未建議派發中期股息。
上海復星醫藥（集團）股份有限公司公佈截至2024年6月30日止六個月的未經審核中期業績。期內，集團實現收入20,383百萬元，較去年同期下降4.38%；銷售成本為10,463百萬元，下降2.21%。銷售及分銷開支為4,266百萬元，下降15.87%；行政開支為2,149百萬元，上升2.19%。研發費用為1,862百萬元，下降12.75%。其他收益為273百萬元，下降68.14%；其他開支為435百萬元，上升69.92%。應佔聯營企業損益為947百萬元，下降15.30%。經營活動產生的現金流量淨額為1,907百萬元，上升5.36%。此外，公司宣佈更換聯席公司秘書及授權代表，甘美霞女士因到齡退休而辭任，陳秀玲女士接任。公司亦進行了A股回購，累計回購1,457,800股，總金額約為人民幣32.3238百萬元。董事會未建議派發中期股息。
Shanghai Fosun Pharma Group Limited announced its unaudited interim performance for the six months ended June 30, 2024. During the period, the Group achieved revenue of 20,383 million yuan, a decrease of 4.38% compared to the same period last year; sales cost was 10,463 million yuan, a decrease of 2.21%. Sales and distribution expenses were 4,266 million yuan, a decrease of 15.87%; administrative expenses were 2,149 million yuan, an increase of 2.19%. Research and development expenses were 1,862 million yuan, a decrease of 12.75%. Other income was 273 million yuan, a decrease of 68.14%; other expenses were 435 million yuan, an increase of 69.92%. Share of profit of associate companies was 947 million yuan, a decrease of 15.30%. Net cash flow from operating activities was 1,907 million yuan, an increase of 5.36%. In addition, the company announced changes to its...Show More
Shanghai Fosun Pharma Group Limited announced its unaudited interim performance for the six months ended June 30, 2024. During the period, the Group achieved revenue of 20,383 million yuan, a decrease of 4.38% compared to the same period last year; sales cost was 10,463 million yuan, a decrease of 2.21%. Sales and distribution expenses were 4,266 million yuan, a decrease of 15.87%; administrative expenses were 2,149 million yuan, an increase of 2.19%. Research and development expenses were 1,862 million yuan, a decrease of 12.75%. Other income was 273 million yuan, a decrease of 68.14%; other expenses were 435 million yuan, an increase of 69.92%. Share of profit of associate companies was 947 million yuan, a decrease of 15.30%. Net cash flow from operating activities was 1,907 million yuan, an increase of 5.36%. In addition, the company announced changes to its joint company secretary and authorized representative, Ms. Gan Meixia resigned due to retirement, and Ms. Chen Xiuling took over. The company also carried out A-share repurchases, repurchasing a total of 1,457,800 shares, with a total amount of approximately RMB 32.3238 million. The board of directors did not recommend the distribution of interim dividends.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated